SLC5A2 and diabetes mellitus: It is for these reasons that we elected to compare GLP-1 receptor agonists to SGLT2 inhibitors, since both medications are used in diabetes of comparable severity, but differ significantly in their mechanism of action, with SGLT2 inhibitors not significantly affecting body adiposity.